LearnGlossaryMarketStocksSuperinvestorsSign in

DYN

Dyne Therapeutics, Inc.

Healthcare · $3.1B market cap

Verdict

We can't put a fair value on DYN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth7.0% a year✗
Sales growth-15.3% a year✗
Free cash flow growth0.3% a year✗
Return on invested capital-51.4%✗

Follow DYN

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 4, 2026: no open-market purchases and 5 sales worth $248K. Why purchases matter

Sales

Cox John

CEO & President · 2026-09-08

Sold

$107K

Kerr Douglas

Chief Medical Officer · 2026-09-08

Sold

$24K

Friedl-Naderer Johanna

Chief Commercial Officer · 2026-09-08

Sold

$3K

Kerr Douglas

Chief Medical Officer · 2026-09-04

Sold

$91K

Friedl-Naderer Johanna

Chief Commercial Officer · 2026-09-04

Sold

$22K

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works